Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

Around the holidays – when many people are baking cookies for Santa, enjoying cocktail parties or having festive family feasts – some adults who use popular medications for diabetes or weight loss ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. Eli Lilly said the FDA approved Zepbound for moderate-to-severe ...

This claim is based on the results of clinical trials that evaluated the effects of the weight loss medications offered through the Ro Body Program, including Zepbound (tirzepatide) and Wegovy ...

This expansion aims to increase production of the company’s highly successful diabetes and weight-loss medications, Mounjaro and Zepbound. The expansion will also add 750 new jobs to the ...

The FDA has not yet approved tirzepatide for weight loss or the management of type 2 diabetes. To approve the generic version of Mounjaro or Zepbound, the FDA will need clear evidence that ...

Pfizer revealed in December that it had decided to drop the twice-daily version, after seeing rates of discontinuation with the drug above 50% in clinical testing, despite weight loss ranging from ...

From 2017 to 2020, it increased to 41.9%. Prescription weight loss medication has become extremely popular because it is easy to take and effective. But, it is expensive, and people must also try ...